Stress and stress reactivity in opioid dependence;Stress und stressreaktivität bei der opioidabhängigkeit- Ein überblick

Schweizer Archiv fur Neurologie und Psychiatrie

Volumn 162, Issue 6, 2011, Pages 239-245

  Gerber, Hana ^a,b   Borgwardt, Stefan J ^a   Gerhard, Urs ^a   Riecher Rössler, Anita ^a   Wiesbeck, Gerhard A ^a   Walter, Marc ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Craving; Diacetylmorphine (DAM); Heroin assisted treatment; Hypothalamic pituitary adrenal (HPA) axis; Opioid dependence; Stress

Indexed keywords

CORTICOTROPIN; DIAMORPHINE; HYDROCORTISONE; METHADONE; OPIATE;

HUMAN; MAINTENANCE THERAPY; OPIATE ADDICTION; RELAPSE; REVIEW; SOCIAL PROBLEM; STRESS;

EID: 80052567828     PISSN: 02587661     EISSN: None     Source Type: Journal    
DOI: 10.4414/sanp.2011.02296     Document Type: Review

References (116)

1. Leshner A.I. Addiction is a brain disease, and it matters. Science. 1997; 278(5335):45-47 (Pubitemid 27446268)
2. Sass H., Wittchen H-U, Zaudig M., Houben I. Diagnostisches und statistisches Manual psychischer Störungen DSM-IV-TR. Textrevision. Übersetzt nach der Textrevision der 4. Auflage des "Diagnostic and statistical manual of mental disorders" der American Psychiatric Association. Göttingen: Hogrefe; 2003.
3. Dilling H, Mombour W, Schmidt MH, editors. Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F). Klinisch-diagnostische Leitlinien. Weltgesundheitsorganisation. 4., durchges. und erg. Auflage. Bern, Göttingen, Toronto, Seattle: Huber; 2000.
4. Le Moal M., Koob G.F. Drug addiction: Pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol. 2007; 17(6-7):377-393 (Pubitemid 46497657)
5. McKay J.R., Alterman A.I., Mulvaney F.D., Koppenhaver J.M. Predicting proximal factors in cocaine relapse and near miss episodes: Clinical and theoretical implications. Drug Alcohol Depend. 1999;56(1):67-78. (Pubitemid 29295380)
6. Epstein D.H., Willner-Reid J., Vahabzadeh M., Mezghanni M., Lin J-L, Preston K.L. Real-time electronic-diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry. 2009;66(1):88-94.
7. Childress A.R., Ehrman R., McLellan A.T., MacRae J., Natale M., O'Brien C.P. Can induced moods trigger drug related responses in opiate abuse patients? J Subst Abuse Treat. 1994;11(1):17-23. (Pubitemid 24113136)
8. Seidenberg A., Honegger U. Methadon, Heroin und andere Opioide. Medizinisches Manual für die ambulante opioidgestützte Behandlung. Bern: Verlag Hans Huber; 1998.
9. Vogel M., Petitjean S., Borgwardt S., Wiesbeck G.A., Walter M. Therapie der Opioidabhängigkeit. Schweizer Arch Neurol. 2010;161(1):5-13.
10. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. (Pubitemid 40973434)
11. Crum R.M. Epidemiology of opioid use, abuse, and dependence. In: Strain EC, Stitzer ML, editors. The treatment of opioid dependence. Baltimore: John Hopkins University Press; 2006. p. 43-55.
12. McBride O., Teesson M., Slade T., Hasin D., Degenhardt L., Baillie A. Further evidence of differences in substance use and dependence between Australia and the United States. Drug Alcohol Depend. 2009; 100(3):258-264
13. Piazza P.V., Le Moal M. The role of stress in drug self-administration. Trends Pharmacol Sci. 1998;19(2):67-74.
14. Kreek M.J., Koob G.F. Drug Dependence: Stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998;51(1-2):23-47. (Pubitemid 28353754)
15. Koob G.F. A role for brain stress systems in addiction. Neuron. 2008; 59(1):11-34. (Pubitemid 351905857)
16. Koob G.F. Brain stress systems in the amygdala and addiction. Brain Res. 2009;1293:61-75.
17. Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology. 2001;158(4):343-359 (Pubitemid 33141310)
18. Kreek MJ. Medical safety, side effects and toxicity of methadone. Proceeding of the Fourth National Conference on Methadone Treatment; 1972. p. 171-74.
19. Kreek M.J. Medical safety and side effects of methadone in tolerant individuals. JAMA. 1973;223(6):665-668
20. Kreek M.J. Medical complications in methadone patients. Ann NY Acad Sci. 1978;311:110-134
21. Cushman Jr P., Kreek M.J. Some endocrinological observations in narcotic addicts. In Zimmerman E, George R, editors. Narcotics and Hypothalamus. New York: Raven Press; 1974. p. 161-173
22. Stimmel B., Kreek M.J. Dependence, tolerance and withdrawal. In Stimmel B, editor. Heroin Dependency: Medical, Economic and Social Aspect. New York: Stratton Intercontinental Medical Book Corp; 1975. p. 88-97.
23. Selye H. A syndrome produced by diverse nocuous agents. Nature. 1936;138(32).
24. Selye H. Studies on adaptation. Endocrinology. 1937;21(2):169-188
25. Selye H. Stress and the General Adaptation Syndrome. Br Med J. 1950; 17(4667):1383-1392
26. Mason J.W. A review of psychoendocrine research on the pituitary-adrenal cortical system. Psychosom Med. 1968;30(5):576-607.
27. Mason J.W. A review of psychoendocrine research on the sympathetic-adrenal medullary system. Psychosom Med. 1968;30(5):631-653
28. Mason J.W. A re-evaluation of the concept of 'non-specifity' in stress theory. J Psychiatr Res. 1971;8(3-4):323-333
29. Lazarus R.S., Folkman S. Stress, appraisal, and coping. New York: Springer; 1984.
30. Biondi M., Picardi A. Psychological stress and neuroendocrine function in humans: The last two decades of research. Psychother Psychosom. 1999;68(3):114-150. (Pubitemid 29209819)
31. Henry J.P. Biological basis of the stress response. Integr Physiol Behav Sci. 1992;27(1):66-83.
32. Kudielka B.M., Kirschbaum C. Biological base of the stress response. In: Al'Absi M, editor. Stress and addiction. Biological and psychological mechanisms. Burlington MA: Elsevier Academic Press; 2007. p. 3-19.
33. Kudielka B.M., Kirschbaum C. Sex differences in HPA axis responses to stress: A review. Biol Psychol. 2005;69(1):113-132 (Pubitemid 40299386)
34. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332(20):1351-1362
35. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000;23(5):477-501.
36. Brown T.T., Wisniewski A.B., Dobs, A.S. Gonadal and adrenal abnormalities in drug users: Cause or consequence of drug use behavior and poor health outcomes. Am J Infect Dis. 2006;2(3):130-135
37. 18F] Cyclofoxy in long term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295(3):1070-1076
38. Kreek M.J. Opiates, opioids and addiction. Mol Psychiatry. 1996;1: 232-254 (Pubitemid 126441297)
39. Kreek M.J. Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Neurochem Res. 1996;21(11):1469-1488 (Pubitemid 26397076)
40. Kreek M.J., LaForge K.S., Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov. 2002;1(9):710-726 (Pubitemid 37361544)
41. Schluger J.H., Bart G., Green M., Ho A., Kreek M.J. Corticotropin- releasing factor testing reveals a dose-dependent difference in methadone maintained vs control subjects. Neuropsychopharmacology. 2003;28(5): 985-994
42. Kiefer F., Wiedemann K. Neuroendocrine pathways of addictive behaviour. Addict Biol. 2004;9(3-4):205-212 (Pubitemid 39491045)
43. Heesch C.M., Negus B.H., Keffer J.H., Snyder R.W., Risser R.C., Eichhorn E.J. Effect of cocaine on cortisol secretion in humans. Am J Med Sci. 1995; 310(2):61-64
44. Walter M., Dammann G., Wiesbeck G.A., Klapp B.F. Psychosozialer Stress und Alkoholkonsum: Wechselwirkungen, Krankheitsprozess und Interventionsmö glichkeiten. Fortschr Neurol Psychiatr. 2005;73(09):517-525 (Pubitemid 41399741)
45. Walter M., Gerhard U., Gerlach M., Weijers H-G, Boening J., Wiesbeck G.A. Cortisol concentrations, stress-coping styles after withdrawal, and longterm abstinence in alcohol dependence. Addict Biol. 2006;11(2):157-162 (Pubitemid 46696808)
46. Eisenman A.J., Fraser H.F., Sloan J., Isbell H. Urinary 17-ketosteroids during a cycle of addiction to morphine. J Pharmacol Exp Ther. 1958;124(4): 305-311
47. Eisenman A.J., Fraser H.F., Brooks J.W. Urinary excretion and plasma levels of 17-hydroxycortikosteroids during a cycle of addiction to morphine. J Pharmacol Exp Ther. 1961;132(2):226-231
48. Facchinetti F., Volpe A., Farci G., Petraglia F., Porro C.A., Barbieri G., et al. Hypothalamus-pituitary-adrenal axis of heroin addicts. Drug Alcohol Depend. 1985;15(4):361-366 (Pubitemid 15234539)
49. George J.M., Reier C.E., Lanese R.R., Rower J.M. Morphine anesthesia blocks cortisol and growth hormone response to surgical stress in humans. J Clin Endocrinol Metab. 1974;38(5):736-741
50. Facchinetti F., Grasso A., Petraglia F., Parrini D., Volpe A., Genazzani A.R. Impaired circadian rhythmicity of ß-lipotrophin, ß-endorphin, and ACTH in heroin addicts. Acta Endocrinol. 1984;105:149-155 (Pubitemid 14219978)
51. Ho W.K.K., Wen H.L., Fung K.P., Ng Y.H., Au K.K., Ma L. Comparison of plasma hormonal levels between heroin-addicted and normal subject. Clin Chim Acta. 1977;75(3):415-419 (Pubitemid 8063621)
52. Kreek M.J., Wardlaw S.L., Hartmann N., Raghunath J., Friedmann J., Schneider B. et al. Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 1983;33(Suppl 1):409-411 (Pubitemid 14249974)
53. Reinke M., Allolio B., Jaursch-Hancke C., Kaulen D., Winkelmann W. Adrenostatische Therapie mit Metyrapon und Aminoglutethimid beim ACTH-abhängigen Cushing-Syndrom. DMW. 1987;112(40):1532-1535 (Pubitemid 18024113)
54. Kreek M.J., Raghunath J., Plevy S., Hamer D., Schneider B., Hartmann N. ACTH, cortisol and ß-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides. 1984;5(1-3):277-278 (Pubitemid 15163382)
55. Schluger J.H., Borg L., Ho A., Kreek M.J. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacology. 2001;24(5): 568-575 (Pubitemid 32244317)
56. Kreek M.J., Hartman N. Chronic use of opioids and antipsychotic drugs: Side effects on endogenous opioids, and toxicity. Ann N Y Acad Sci. 1982;398:151-172 (Pubitemid 13026044)
57. Walter M., Wiesbeck G.A., Bloch N., Aeschbach S., Olbrich H.M., Seifritz E., et al. Psychobiological responses to drug cues before and after metha done intake in heroin dependent patients: A pilot study. Eur Neuropsychopharmacol. 2008;18(5):390-393
58. Camí J., Gilabert M., San L., De La Torre R. Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts. Brit J Addict. 1992;87:1145-1151
59. Culpepper-Morgan J.A., Kreek M.J. Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: A case of naloxone-induced withdrawal. Metabolis. 1997;46(2):130-134 (Pubitemid 27078754)
60. Volavka J., Cho D., Mallya A., Baumann J. Naloxone increases ACTH and Cortisol levels in man. N Engl J Med. 1979;300(18):1056-1057 (Pubitemid 9193267)
61. Stine S.M., Grillon C.G., Morgan C.A., Kosten T.R., Charney D.S., Krystal J.H. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology. 2001;154(3):274-281 (Pubitemid 32247188)
62. Aouzerate B., Ho A., Schluger J.H., Perret G., Borg L., Le Moal M., et al. Glucocorticoid negative feedback in methadone-maintained former heroin addicts with ongoing cocaine dependence: Dose-response to dexamethasone suppression. Addict Biol. 2006;11(1):84-96. (Pubitemid 46696740)
63. Walter M., Wiesbeck G.A., Degen B., Albrich J., Oppel M., Schulz A., et al. Heroin reduces startle and cortisol response in opioid-maintained heroindependent patients. Addict Biol. 2011;16(1):145-151
64. Koob G.F., Le Moal M. Neurobiology of Addiction. Elsevier: London; 2006.
65. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol. 2008;59:29-53.
66. Koob G.F., Volkow N.D. Neurocircuitry of Addiction. Neuropsychopharmacology Rev. 2010;35:217-238
67. Koob G.F., Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci. 2005;8(11):1442-1444 (Pubitemid 41573653)
68. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001;24(2):97-129.
69. Feltenstein M.W., See R.E. The neurocircuitry of addiction: An overview. Brit J Pharmacol. 2008;154(2):261-274 (Pubitemid 351670601)
70. Volkow N.D., Fowler, J.S., Wang G-J. The addicted human brain: Insights from imaging studies. J Clin Invest. 2003;111(10):1444-1451 (Pubitemid 38063274)
71. Kalivas P.W., Volkow N.D. The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry. 2005;162(8):1403-1413 (Pubitemid 41105554)
72. Volkow N.D. What do we know about drug addiction? Am J Psychiatry. 2005;162(8):1401-1402 (Pubitemid 41105553)
73. Volkow N.D., Fowler, J.S. Addiction, a disease of compulsion and drive: Involvement of the orbitofrontal cortex. Cereb Cortex. 2000;10(3): 318-325 (Pubitemid 30159298)
74. Citri A., Malenka R.C. Synaptic Plasticity: Multiple forms, functions, and mechanisms. Neuropsychopharmacology. 2008;33(1):18-41. (Pubitemid 350191314)
75. Kalivas P.W., O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology. 2008;33(1):166-180 (Pubitemid 350191316)
76. Kalivas P., Husseini K.M. Neuroplasticity: A new window on therapeutics in neuropsychiatric disease. Neuropsychopharmacology. 2008;33(1):2. (Pubitemid 350191334)
77. Sterling P., Eyer J. Allostasis: A new paradigm to explain arousal pathology. In Fisher S, Reason J, editors. Handbook of life stress, cognition and health. Chichester: John Wiley; 1988. p. 629-649
78. Sterling P., Eyer J. Biological basis of stress related mortality. Social Sci Med Part E: Med Psychol. 1981;15(1):3-42. (Pubitemid 11157934)
79. Grillon C., Duncko R., Coivington M.F., Kopperman L., Kling M.A. Acute stress potentiates anxiety in humans. Biol Psychiatry. 2007;62(10): 1183-1186 (Pubitemid 350047461)
80. Young E.A., Abelson J.L., Curtis G.C., Nesse R.M. Childhood adversity and vulnerability to mood and anxiety disorders. Depress Anxiety. 1997;5(2): 66-72.
81. Sinha R., Talih M., Malison R., Cooney N., Anderson G.M., Kreek M.J. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology. 2003;170(1):62-72. (Pubitemid 37372479)
82. Sinha R., Garcia M., Paliwal P., Kreek M.J., Rounsaville B.J. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcome. Arch Gen Psychiatry. 2006;63(3): 324-331 (Pubitemid 43345357)
83. Sinha R., Fuse T., Aubin L-R, O'Malley S.S. Psychological stress, drug related cues and cocaine craving. Psychopharmacology. 2000;152(2): 140-148
84. Fox H.C., Talih M., Malison R., Anderson G.M., Kreek M.J., Sinha R. Frequency of recent cocaine and alcohol use affects drug craving and associated responses to stress and drug-related cues. Psychoneuroendocrinology. 2005;30(9):880-891 (Pubitemid 40977910)
85. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology. 2003;168(1-2):3-20. (Pubitemid 36851158)
86. Shalev U., Highfiled D., Yap J., Shaham Y. Stress and relapse to drug seeking in rats: Studies on generality of the effect. Psychopharmocology. 2000;150(3):337-346 (Pubitemid 30447854)
87. Aguilar de Arcos F., Verdejo-García A., Ceverino A., Montañez-Pareja M., López-Juárez E., Sánchez-Barrera M., et al. Dysregulation of emotional response in current and abstinent heroin users: Negative heightening and positive blunting. Psychopharmocology. 2008;198(2):159-166
88. Khantzian E.J. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harv Rev Psychiatry. 1997;4(5):231-244 (Pubitemid 27086599)
89. King V.L., Peirce J., Brooner R.K. Comorbid psychiatric disorders. In: Strain EC, Stitzer ML, editors. The treatment of opioid dependence. Baltimore: Johns Hopkins University Press; 2006. p. 421-451
90. Dürsteler-MacFarland K.M., Stohler R., Moldovanyi A., Rey S., Basdekis R., Gschwend P., et al. Complaints of heroin-maintained patients: A survey of symptoms ascribed to diacetylmorphine. Drug Alcohol Depend. 2006; 81(3):231-2399.
91. Kreek M.J. Clinical Update of opioid agonist and partial agonist medications for the maintenance treatment of opioid Addiction. Semin Neurosci. 1997;9(3-4):140-157 (Pubitemid 27490190)
92. Die Heroingestützte Behandlung/Behandlung mit Diacetylmorphin (HeGeBe) im Jahre 2008. Bundesamt für Gesundheit (BAG). Bern; 2009.
93. Stoller K.B., Bigelow G.E. Introduction and historical overview. In: Strain EC, Stitzer ML, editors. The treatment of opioid dependence. Baltimore: Johns Hopkins University Press; 2006. p. 3-17.
94. Oviedo-Joekes E., Brissette S., Marsh D.C., Lauzon P., Guh D., Anis A., et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777-786
95. Uchtenhagen A. Heroin-assisted treatment in Switzerland: A case study in policy change. Addiction. 2010;105(1):29-37.
96. Uchtenhagen A. Heroingestützte Behandlung. In Beubler E, Haltmayer H, Springer A, editors. Opiatabhängigkeit: interdisziplinäre Aspekte für die Praxis. 2. Auflage. Wien, New York: Springer-Verlag; 2007. p. 205-212
97. Blanken P., Hendriks V.M., Koeter M.V.J., Van Ree J.M., Van den Brink W. Matching of treatment resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: Results from two randomized controlled trials. Addiction. 2005;100(1):89-95.
98. Haasen C., Verthein U., Degkwitz P., Berger J., Krausz M., Naber D. Heroin-assisted treatment for opioid dependence. Randomized controlled trial. Brit J Psychiatry. 2007;191(1):55-62. (Pubitemid 47035182)
99. Rehm J., Gschwend P., Steffen T., Gutzwiller F., Dobler-Mikola A., Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet. 2001;358(9291):1417-1420 (Pubitemid 33055744)
100. Van den Brink W., Hendricks V.M., Blanken P., Koeter M.W.J., Van Zwieten B.J., Van Ree J.M. Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. BMJ. 2003;327(310).
101. Verthein U., Bonorden-Kleij K., Degwitz P., Dilg C., Köhler W.K., Passie T., et al. Long-term effects of heroin-assisted treatment in Germany. Addiction. 2008;103(6):960-966 (Pubitemid 351703473)
102. Stohler R., Dürsteler K.M., Störmer R., Seifritz E., Hug I., Sattler-Mayr J., et al. Rapid cortical hemoglobin deoxygenation after heroin and methadone injection in humans: A preliminary report. Drug Alcohol Depend. 1999;57(1):23-28 (Pubitemid 29452952)
103. Frick U., Rehm J., Zullino D., Fernando M., Wiesbeck G., Amman J., et al. Long-term follow-up of orally administered diacetylmorphine substitution treatment. Eur Addict Res. 2010;16(3):131-138
104. Meili D., Broers B., Bruggmann P., Fink A., Hämmig R. Medizinische Empfehlungen für substitutionsgestützte Behandlung (SGB) bei Opioidabhängigkeit. SSAM. Bern; 2007.
105. Walter M., Gunderson J.G., Zanarini M.C., Sanislow C., Grilo C.M., McGlashan T.H., et al. New Onsets of Substance Use Disorders in Borderline Personality Disorder Over Seven Years of Follow-ups: Findings from the Collaborative Longitudinal Personality Disorders Study. Addiction. 2009;204(1):97-103.
106. Steiner J. Orte des seelischen Rückzuges. 3. Auflage. Stuttgart: Klett-Cotta; 2006.
107. Kernberg O.F. Schwere Persönlichkeitsstörungen: Theorie, Diagnose, Behandlungsstrategien. 7. Auflage. Stuttgart: Klett-Cotta; 2006.
108. Kernberg O.F. Wut und Hass. 3. Auflage. Stuttgart: Klett-Cotta; 2000.
109. Dammann G., Janssen P.L. Psychotherapie der Borderline-Störungen. 2. Auflage. Stuttgart: Georg Thieme; 2007.
110. Sollberger D., Walter M. Psychotherapie der Borderline- Persönlichkeitsstörung: Gemeinsamkeiten und Differenzen evidenzbasierter störungsspezifischer Behandlungen. Fortschr Neurol Psychiatr. 2010;78(12): 698-708.
111. Möller H-J, Laux G., Deister A., Braun-Scharm H. Psychiatrie und Psychotherapie. 3. überarb. Auflage. Stuttgart: Georg Thieme; 2005.
112. Stitzer M.L., Sigmon S.C. Other substance use disorders: Prevalence, consequences, detection, and management. In: Strain EC, Stitzer ML, editors. The treatment of opioid dependence. Baltimore: Johns Hopkins University Press; 2006. p. 365-397
113. Fingerhood M.I. Comorbid medical disorders. In: Strain EC, Stitzer ML, editors. The treatment of opioid dependence. Baltimore: Johns Hopkins University Press; 2006. p. 398-420.
114. Nordt C., Stohler R. Incidence of heroin use in Zurich, Switzerland: A treatment case register analysis. Lancet. 2006;367(9525):1830-1834 (Pubitemid 43833193)
115. Langleben D.D., Ruparel K., Elman I., Busch-Winokur S., Pratiwadi R., Loughead J., et al. Acute effect of methadone maintenance dose on brain fMRI response to heroin-related cues. Am J Psychiatry. 2008;165(3): 390-394 (Pubitemid 351704496)
116. Walter M., Wiesbeck G.A., Riecher-Rössler A., Borgwardt S.J. Neural effects of heroin - Relation to anxiety and stress. Progr Neuro Psychoph. 2010;34(5):816-817